By |

Profile

Neurotrope Inc is a biopharmaceutical company. The company is principally focused on developing a product platform based on a drug candidate called bryostatin for the treatment of Alzheimer's disease ("AD"), which is in the clinical testing stage. It is also developing bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C, which are in pre-clinical testing.

Contact Information

Website: www.neurotropebioscience.com
Email: investor@ibcadvancedalloys.com
Main Phone: +1 973 242-0005
Address: 205 East 42nd Street
Address 2: 17th Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10017

Issuer Information

Exchange: NSC
CEO: Charles S. Ryan
Employees: 5
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Neurotrope Inc is a biopharmaceutical company. The company is principally focused on developing a product platform based on a drug candidate called bryostatin for the treatment of Alzheimer's disease ("AD"), which is in the clinical testing stage. It is also developing bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C, which are in pre-clinical testing.

Contact Information

Website: www.neurotropebioscience.com
Email: investor@ibcadvancedalloys.com
Main Phone: +1 973 242-0005
Address: 205 East 42nd Street
Address 2: 17th Floor
State: NY
City / Town: New York
Country: USA
Postal Code: 10017

Issuer Information

Exchange: NSC
CEO: Charles S. Ryan
Employees: 5
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 3.95 $ -0.07 (-1.74%)
Last Price 3.95 Change $ -0.07 Change % -1.74 Tick N/A
Bid 3.33 Bid Size 100.00 Ask 8.58 Ask Size 15,000.00
Open 4.01 High 4.06 Low 3.95 Prev Close 4.02
Last Trade Volume 25,078 52 Wk Hi 11.93 52 Wk Low 3.33
Market Cap 31.2 mi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 7,909,693.00 EPS (TTM) -1.48 PE Ratio N/A Exchange NCM
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 16 16 16 16
Low Target Price Estimate 15 15 15 15
Mean Target Price Estimate 15.5 15.5 15.5 15.5
Standard Deviation 0.71 0.71 0.71 0.71
Date of Most Recent Estimate 05/17/18 05/17/18 05/17/18 05/17/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 2 1 1 2
Moderate Buy 0 0 0 0
Hold 0 0 0 0
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1 1 1 1